Please login to the form below

Not currently logged in
Email:
Password:

Ruvise

This page shows the latest Ruvise news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws application for Ruvise approval in EU

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension. The European Medicines Agency (EMA) has said that Novartis has withdrawn its marketing application for Ruvise in the treatment of high blood pressure. ... Ruvise (imatinib mesylate) is already

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics